Taipei, Taiwan – October 16, 2026
Mycenax Biotech Inc. (4726) was honored with the 2026 Taiwan BIO Awards – Emerging Company of the Year and invited to attend a reception hosted by President Lai Ching-te at the Presidential Office on October 1, 2026. The event brought together recipients of the 2026 Taiwan BIO Awards, recognizing the achievements of Taiwan's biotechnology industry in innovation, technological advancement, and international competitiveness.
The reception followed Mycenax's award recognition in July, marking another milestone in the company's continued development as a biologics Contract Development and Manufacturing Organization (CDMO). In recent years, Mycenax has successfully advanced two internationally marketed biologic products into commercial manufacturing, supporting supply to 13 countries worldwide. The company has also successfully passed multiple international regulatory inspections, further strengthening its capabilities in biologics development, manufacturing, and quality management.
As part of its international expansion strategy, Mycenax continues to deepen strategic partnerships between Taiwan and Japan, develop a cross-border biologics manufacturing network, and expand its capabilities in next-generation biologics, including antibody-drug conjugates (ADCs). These efforts further enhance the company's integrated CDMO services, from early-stage development through commercial manufacturing.
The award recognition and Presidential Office reception reflect the dedication of the Mycenax team to advancing biologics development, manufacturing, and global market expansion. Moving forward, Mycenax will continue to pursue its "Big D, Strong M" strategy, combining innovative development capabilities with scalable manufacturing capacity, strengthening international partnerships, and delivering high-quality, competitive CDMO services to global biopharmaceutical partners.
Image 1
Pei-Jiun Chen, Ph.D., CEO and President of Mycenax Biotech Inc., greets President Lai Ching-te during the reception at the Presidential Office on October 1, 2026.
Image 2
Group photo of the 2026 Taiwan BIO Awards recipients and officials at the Presidential Office.
Photo credit: Presidential Office
Related Links
-
Presidential Office: President Lai Receives Recipients of the 2026 Taiwan BIO Awards
-
Mycenax Receives the 2026 Taiwan BIO Awards – Emerging Company of the Year
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) with scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
Taipei, Taiwan – October 16, 2026
Mycenax Biotech Inc. (4726) was honored with the 2026 Taiwan BIO Awards – Emerging Company of the Year and invited to attend a reception hosted by President Lai Ching-te at the Presidential Office on October 1, 2026. The event brought together recipients of the 2026 Taiwan BIO Awards, recognizing the achievements of Taiwan's biotechnology industry in innovation, technological advancement, and international competitiveness.
The reception followed Mycenax's award recognition in July, marking another milestone in the company's continued development as a biologics Contract Development and Manufacturing Organization (CDMO). In recent years, Mycenax has successfully advanced two internationally marketed biologic products into commercial manufacturing, supporting supply to 13 countries worldwide. The company has also successfully passed multiple international regulatory inspections, further strengthening its capabilities in biologics development, manufacturing, and quality management.
As part of its international expansion strategy, Mycenax continues to deepen strategic partnerships between Taiwan and Japan, develop a cross-border biologics manufacturing network, and expand its capabilities in next-generation biologics, including antibody-drug conjugates (ADCs). These efforts further enhance the company's integrated CDMO services, from early-stage development through commercial manufacturing.
The award recognition and Presidential Office reception reflect the dedication of the Mycenax team to advancing biologics development, manufacturing, and global market expansion. Moving forward, Mycenax will continue to pursue its "Big D, Strong M" strategy, combining innovative development capabilities with scalable manufacturing capacity, strengthening international partnerships, and delivering high-quality, competitive CDMO services to global biopharmaceutical partners.
Image 1
Pei-Jiun Chen, Ph.D., CEO and President of Mycenax Biotech Inc., greets President Lai Ching-te during the reception at the Presidential Office on October 1, 2026.
Image 2
Group photo of the 2026 Taiwan BIO Awards recipients and officials at the Presidential Office.
Photo credit: Presidential Office
Related Links
-
Presidential Office: President Lai Receives Recipients of the 2026 Taiwan BIO Awards
-
Mycenax Receives the 2026 Taiwan BIO Awards – Emerging Company of the Year
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) with scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
